Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CardioCell in Acute Myocardial Infarction
NCT03404063Phase 3Completed
- Sponsor
- Krakowski Szpital Specjalistyczny im. Jana Pawła II
- Start
- Oct 2017
- Primary completion
- Jul 2020
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ischemia-tolerant mesenchymal stem cells in acute myocardial infarction (AMI) (2 arms), sponsored by Krakowski Szpital Specjalistyczny im. Jana Pawła II. Primary endpoint: Reduction of infarct size at 6 months. Started Oct 2017; status: completed.
02
Drugs
ischemia-tolerant mesenchymal stem cells
03
Conditions
acute myocardial infarction (AMI)
Beyond the preview
Go deeper on NCT03404063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03404063.